Annual EBIT
-$152.99 M
-$48.31 M-46.15%
December 31, 2023
Summary
- As of February 8, 2025, KROS annual earnings before interest & taxes is -$152.99 million, with the most recent change of -$48.31 million (-46.15%) on December 31, 2023.
- During the last 3 years, KROS annual EBIT has fallen by -$107.47 million (-236.05%).
- KROS annual EBIT is now -11481.53% below its all-time high of -$1.32 million, reached on December 31, 2018.
Performance
KROS EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBIT
-$58.66 M
-$8.22 M-16.29%
September 30, 2024
Summary
- As of February 8, 2025, KROS quarterly earnings before interest & taxes is -$58.66 million, with the most recent change of -$8.22 million (-16.29%) on September 30, 2024.
- Over the past year, KROS quarterly EBIT has dropped by -$29.15 million (-98.80%).
- KROS quarterly EBIT is now -2480.60% below its all-time high of -$2.27 million, reached on June 30, 2019.
Performance
KROS Quarterly EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBIT
-$187.09 M
-$15.38 M-8.96%
September 30, 2024
Summary
- As of February 8, 2025, KROS TTM earnings before interest & taxes is -$187.09 million, with the most recent change of -$15.38 million (-8.96%) on September 30, 2024.
- Over the past year, KROS TTM EBIT has dropped by -$34.09 million (-22.28%).
- KROS TTM EBIT is now -6886.00% below its all-time high of -$2.68 million, reached on March 31, 2019.
Performance
KROS TTM EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBIT Formula
EBIT = Revenue − COGS − Operating Expenses
KROS EBIT Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -46.1% | -98.8% | -22.3% |
| 3 y3 years | -236.1% | -188.5% | -199.5% |
| 5 y5 years | -10000.0% | -1554.2% | -1563.4% |
KROS EBIT Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -169.7% | at low | -1087.4% | at low | -229.8% | at low |
| 5 y | 5-year | -1141.0% | at low | -2033.0% | at low | -1563.4% | at low |
| alltime | all time | <-9999.0% | at low | -2480.6% | at low | -6886.0% | at low |
Keros Therapeutics EBIT History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$58.66 M(+16.3%) | -$187.09 M(+9.0%) |
| Jun 2024 | - | -$50.44 M(+4.0%) | -$171.71 M(+5.6%) |
| Mar 2024 | - | -$48.48 M(+64.3%) | -$162.61 M(+6.3%) |
| Dec 2023 | -$152.99 M(+46.2%) | -$29.51 M(-31.8%) | -$152.99 M(-0.1%) |
| Sep 2023 | - | -$43.28 M(+4.7%) | -$153.20 M(+14.8%) |
| Jun 2023 | - | -$41.34 M(+6.3%) | -$133.43 M(+11.8%) |
| Mar 2023 | - | -$38.87 M(+30.8%) | -$119.36 M(+14.0%) |
| Dec 2022 | -$104.68 M(+84.5%) | -$29.72 M(+26.4%) | -$104.68 M(+31.0%) |
| Sep 2022 | - | -$23.51 M(-13.8%) | -$79.90 M(+4.1%) |
| Jun 2022 | - | -$27.27 M(+12.7%) | -$76.72 M(+17.9%) |
| Mar 2022 | - | -$24.18 M(+389.6%) | -$65.08 M(+14.7%) |
| Dec 2021 | -$56.73 M | -$4.94 M(-75.7%) | -$56.73 M(-9.2%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2021 | - | -$20.33 M(+30.2%) | -$62.46 M(+15.3%) |
| Jun 2021 | - | -$15.62 M(-1.3%) | -$54.16 M(+9.9%) |
| Mar 2021 | - | -$15.83 M(+48.3%) | -$49.30 M(+8.3%) |
| Dec 2020 | -$45.53 M(+269.3%) | -$10.68 M(-11.3%) | -$45.53 M(+21.1%) |
| Sep 2020 | - | -$12.03 M(+11.9%) | -$37.60 M(+29.2%) |
| Jun 2020 | - | -$10.76 M(-10.8%) | -$29.11 M(+41.1%) |
| Mar 2020 | - | -$12.06 M(+338.6%) | -$20.63 M(+83.4%) |
| Dec 2019 | -$12.33 M(+833.2%) | -$2.75 M(-22.4%) | -$11.25 M(+32.4%) |
| Sep 2019 | - | -$3.55 M(+56.0%) | -$8.50 M(+71.6%) |
| Jun 2019 | - | -$2.27 M(-15.1%) | -$4.95 M(+84.9%) |
| Mar 2019 | - | -$2.68 M | -$2.68 M |
| Dec 2018 | -$1.32 M | - | - |
FAQ
- What is Keros Therapeutics annual earnings before interest & taxes?
- What is the all time high annual EBIT for Keros Therapeutics?
- What is Keros Therapeutics annual EBIT year-on-year change?
- What is Keros Therapeutics quarterly earnings before interest & taxes?
- What is the all time high quarterly EBIT for Keros Therapeutics?
- What is Keros Therapeutics quarterly EBIT year-on-year change?
- What is Keros Therapeutics TTM earnings before interest & taxes?
- What is the all time high TTM EBIT for Keros Therapeutics?
- What is Keros Therapeutics TTM EBIT year-on-year change?
What is Keros Therapeutics annual earnings before interest & taxes?
The current annual EBIT of KROS is -$152.99 M
What is the all time high annual EBIT for Keros Therapeutics?
Keros Therapeutics all-time high annual earnings before interest & taxes is -$1.32 M
What is Keros Therapeutics annual EBIT year-on-year change?
Over the past year, KROS annual earnings before interest & taxes has changed by -$48.31 M (-46.15%)
What is Keros Therapeutics quarterly earnings before interest & taxes?
The current quarterly EBIT of KROS is -$58.66 M
What is the all time high quarterly EBIT for Keros Therapeutics?
Keros Therapeutics all-time high quarterly earnings before interest & taxes is -$2.27 M
What is Keros Therapeutics quarterly EBIT year-on-year change?
Over the past year, KROS quarterly earnings before interest & taxes has changed by -$29.15 M (-98.80%)
What is Keros Therapeutics TTM earnings before interest & taxes?
The current TTM EBIT of KROS is -$187.09 M
What is the all time high TTM EBIT for Keros Therapeutics?
Keros Therapeutics all-time high TTM earnings before interest & taxes is -$2.68 M
What is Keros Therapeutics TTM EBIT year-on-year change?
Over the past year, KROS TTM earnings before interest & taxes has changed by -$34.09 M (-22.28%)